ロード中...
Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness
Background: Glioblastoma (GB) is one of the most common (~30%) and lethal cancers of the central nervous system. Although new therapies are emerging, chemoresistance to treatment is one of the major challenges in cancer treatment. Brain cytoplasmic 200 (BC200) RNA, also known as BCYRN1, is a long no...
保存先:
| 出版年: | Cells |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7463574/ https://ncbi.nlm.nih.gov/pubmed/32784466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9081859 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|